TY - JOUR
T1 - NCCN debuts new guidelines for myeloproliferative neoplasms
AU - Mesa, Ruben A.
N1 - Publisher Copyright:
© JNCCN
PY - 2017/5
Y1 - 2017/5
N2 - For the first time, NCCN has published guidelines specifically geared toward treating myeloproliferative neoplasms (MPNs). The first set of guidelines was developed for myelofibrosis (MF), and was presented at the NCCN 22nd Annual Conference. Future guidelines will be issued for polycythemia vera, essential thrombocytopenia, and atypical MPNs. Patients with MF can have an unpredictable course, one that is largely dependent on the presence of certain molecular alterations. Models are currently emerging that take into account molecular factors. Only one drug is currently approved for MF, the oral JAK1/2 inhibitor ruxolitinib, which has been shown to significantly reduce splenomegaly and improve symptoms.
AB - For the first time, NCCN has published guidelines specifically geared toward treating myeloproliferative neoplasms (MPNs). The first set of guidelines was developed for myelofibrosis (MF), and was presented at the NCCN 22nd Annual Conference. Future guidelines will be issued for polycythemia vera, essential thrombocytopenia, and atypical MPNs. Patients with MF can have an unpredictable course, one that is largely dependent on the presence of certain molecular alterations. Models are currently emerging that take into account molecular factors. Only one drug is currently approved for MF, the oral JAK1/2 inhibitor ruxolitinib, which has been shown to significantly reduce splenomegaly and improve symptoms.
UR - http://www.scopus.com/inward/record.url?scp=85043386625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043386625&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2017.0083
DO - 10.6004/jnccn.2017.0083
M3 - Article
C2 - 28515254
AN - SCOPUS:85043386625
SN - 1540-1405
VL - 15
SP - 720
EP - 722
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5S
ER -